newsfilter
← Latest News
GlobeNewswire·

Turn Therapeutics Appoints Dr. Kent Kester to Board of Directors

  • Turn Therapeutics announced the appointment of Dr. Kent E. Kester to its Board of Directors.
  • Dr. Kester is a retired U.S. Army Colonel with extensive experience in clinical development, vaccine innovation, & public-private collaboration.
  • He previously served as Commander of the Walter Reed Army Institute of Research & Executive Director of Vaccine Research & Development at CEPI.
  • CEO Bradley Burnam stated Dr. Kester's expertise will strengthen governance & support late-stage programs in infectious disease.
  • Dr. Kester expressed commitment to Turn's mission of addressing serious infectious & inflammatory diseases with innovative science.
  • Turn Therapeutics holds three FDA clearances for wound & dermatology formulations & is advancing late-stage trials for eczema & onychomycosis.
  • The company pursues global health initiatives involving thermostable vaccine delivery for underserved regions.